{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:14:41Z","timestamp":1792682081305,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016175","name":"Chulabhorn Royal Academy","doi-asserted-by":"publisher","award":["PSCM2568\/003"],"award-info":[{"award-number":["PSCM2568\/003"]}],"id":[{"id":"10.13039\/100016175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18294-2","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:46:17Z","timestamp":1759751177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review and meta-analysis of the global prevalence of fluoroquinolone resistant Morganella morganii clinical isolates"],"prefix":"10.1038","volume":"15","author":[{"given":"Kannipa","family":"Tasanapak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutthirat","family":"Sitthisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thawatchai","family":"Kitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiriya","family":"Mahikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriwat","family":"Kucharoenphaibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintana","family":"Wongwigkarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontaphat","family":"Leerach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"18294_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jiph.2023.12.013","volume":"17","author":"A Alsaadi","year":"2024","unstructured":"Alsaadi, A. et al. Epidemiology and clinical characteristics of Morganella morganii infections: A multicenter retrospective study. J. Infect. Public Health 17, 430\u2013434. https:\/\/doi.org\/10.1016\/j.jiph.2023.12.013 (2024).","journal-title":"J. Infect. Public Health"},{"key":"18294_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1099\/jmm.0.008821-0","volume":"58","author":"S Ghosh","year":"2009","unstructured":"Ghosh, S., Bal, A. M., Malik, I. & Collier, A. Fatal Morganella morganii bacteraemia in a diabetic patient with gas gangrene. J. Med. Microbiol. 58, 965\u2013967. https:\/\/doi.org\/10.1099\/jmm.0.008821-0 (2009).","journal-title":"J. Med. Microbiol."},{"issue":"3","key":"18294_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jmii.2017.08.010","volume":"52","author":"D Erlanger","year":"2019","unstructured":"Erlanger, D., Assous, M. V., Wiener-Well, Y., Yinnon, A. M. & Ben-Chetrit, E. Clinical manifestations, risk factors and prognosis of patients with Morganella morganii sepsis. J. Microbiol. Immunol. Infect. 52(3), 443\u2013448. https:\/\/doi.org\/10.1016\/j.jmii.2017.08.010 (2019).","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"7","key":"18294_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1469-0691.2007.01715.x","volume":"13","author":"KB Laupland","year":"2007","unstructured":"Laupland, K. B., Parkins, M. D., Ross, T. & Pitout, J. D. Population-based laboratory surveillance for tribe Proteeae isolates in a large Canadian health region. Clin. Microbiol. Infect. 13(7), 683\u2013688. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01715.x (2007).","journal-title":"Clin. Microbiol. Infect."},{"key":"18294_CR5","doi-asserted-by":"publisher","first-page":"0056922","DOI":"10.1128\/spectrum.00569-22","volume":"10","author":"KB Laupland","year":"2022","unstructured":"Laupland, K. B., Paterson, D. L., Edwards, F., Stewart, A. G. & Harris, P. N. A. Morganella morganii, an emerging cause of bloodstream infections. Microbiol. Spectr. 10, 0056922. https:\/\/doi.org\/10.1128\/spectrum.00569-22 (2022).","journal-title":"Microbiol. Spectr."},{"issue":"12","key":"18294_CR6","doi-asserted-by":"publisher","first-page":"744291","DOI":"10.3389\/FMICB.2021.744291","volume":"28","author":"G Xiang","year":"2021","unstructured":"Xiang, G. et al. Clinical molecular and genomic epidemiology of Morganella morganii in China. Front. Microbiol. 28(12), 744291. https:\/\/doi.org\/10.3389\/FMICB.2021.744291 (2021).","journal-title":"Front. Microbiol."},{"key":"18294_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5144\/0256-4947.2016.223","volume":"36","author":"AS Al-Muhanna","year":"2016","unstructured":"Al-Muhanna, A. S., Al-Muhanna, S. & Alzuhairi, M. A. Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann. Saudi Med. 36, 223\u2013228. https:\/\/doi.org\/10.5144\/0256-4947.2016.223 (2016).","journal-title":"Ann. Saudi Med."},{"key":"18294_CR8","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"WH Sheng","year":"2013","unstructured":"Sheng, W. H., Badal, R. E. & Hsueh, P. R. Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: Results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob. Agents. Chemother. 57, 2981\u20132988. https:\/\/doi.org\/10.1128\/AAC.00971-12 (2013).","journal-title":"Antimicrob. Agents. Chemother."},{"key":"18294_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-014-0034-4","volume":"13","author":"M Nasri Yaiche","year":"2014","unstructured":"Nasri Yaiche, M. et al. Type II and type IV topoisomerase mutations in clinical isolates of Morganella morganii harbouring the qnrD gene. Ann. Clin. Microbiol. Antimicrob. 13, 34. https:\/\/doi.org\/10.1186\/s12941-014-0034-4 (2014).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"18294_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/genes14061279","volume":"14","author":"DU Behera","year":"2023","unstructured":"Behera, D. U. et al. Sequencing and characterization of M. morganii strain UM869: A comprehensive comparative genomic analysis of virulence, antibiotic resistance, and functional pathways. Genes 14, 1279. https:\/\/doi.org\/10.3390\/genes14061279 (2023).","journal-title":"Genes"},{"key":"18294_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10156-010-0120-2","volume":"17","author":"JM Rodriguez-Martinez","year":"2011","unstructured":"Rodriguez-Martinez, J. M., Cano, M. E., Velasco, C., Martinez-Martinez, L. & Pascual, A. Plasmid-mediated quinolone resistance: An update. J. Infect. Chemother. 17, 149\u2013182. https:\/\/doi.org\/10.1007\/s10156-010-0120-2 (2011).","journal-title":"J. Infect. Chemother."},{"key":"18294_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0732-8893(02)00381-4","volume":"43","author":"WH Sheng","year":"2002","unstructured":"Sheng, W. H. et al. Emerging fluoroquinolone-resistance for common clinically important Gram-negative bacteria in Taiwan. Diagn. Microbiol. Infect. Dis. 43, 141\u2013147. https:\/\/doi.org\/10.1016\/S0732-8893(02)00381-4 (2002).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR13","doi-asserted-by":"publisher","first-page":"744291","DOI":"10.3389\/fmicb.2021.744291","volume":"12","author":"G Xiang","year":"2021","unstructured":"Xiang, G. et al. Clinical molecular and genomic epidemiology of Morganella morganii in China. Front. Microbiol. 12, 744291. https:\/\/doi.org\/10.3389\/fmicb.2021.744291 (2021).","journal-title":"Front. Microbiol."},{"key":"18294_CR14","doi-asserted-by":"publisher","first-page":"ofad265","DOI":"10.1093\/ofid\/ofad265","volume":"10","author":"D Ince","year":"2023","unstructured":"Ince, D. et al. Epidemiology of Gram-negative bloodstream infections in the United States: Results from a cohort of 24 hospitals. Open Forum Infect. Dis. 10, ofad265. https:\/\/doi.org\/10.1093\/ofid\/ofad265 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"18294_CR15","doi-asserted-by":"publisher","first-page":"1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 6, 1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100 (2009).","journal-title":"PLoS Med."},{"key":"18294_CR16","doi-asserted-by":"publisher","first-page":"1163439","DOI":"10.3389\/fmed.2023.1163439","volume":"10","author":"M Banar","year":"2023","unstructured":"Banar, M. et al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: A systematic review and meta-analysis. Front. Med. 10, 1163439. https:\/\/doi.org\/10.3389\/fmed.2023.1163439 (2023).","journal-title":"Front. Med."},{"key":"18294_CR17","unstructured":"Joanna Briggs Institute. Checklist for analytical cross sectional studies. (2017)."},{"key":"18294_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jgar.2023.05.006","volume":"36","author":"X Xu","year":"2024","unstructured":"Xu, X., Zhang, X., Zhang, G. & Abbasi Tadi, D. Prevalence of antibiotic resistance of Staphylococcus aureus in cystic fibrosis infection: A systematic review and meta-analysis. J. Glob. Antimicrob. Resist. 36, 419\u2013425. https:\/\/doi.org\/10.1016\/j.jgar.2023.05.006 (2024).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"18294_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13756-019-0673-5","volume":"8","author":"N Droz","year":"2019","unstructured":"Droz, N. et al. Bacterial pathogens and resistance causing community acquired paediatric bloodstream infections in low- and middle-income countries: A systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 8, 207. https:\/\/doi.org\/10.1186\/s13756-019-0673-5 (2019).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"18294_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186 (2002).","journal-title":"Stat. Med."},{"key":"18294_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5530\/jyp.2021.13.95","volume":"13","author":"NJ Ahmed","year":"2021","unstructured":"Ahmed, N. J., Abdalla, M., Alahmadi, H., Haseeb, A. & Khan, A. H. Prevalence of Gram-negative and Gram-positive bacteria and antibiotic resistance rates at a military hospital in Riyadh region. J. Young Pharm. 13, 392\u2013395. https:\/\/doi.org\/10.5530\/jyp.2021.13.95 (2021).","journal-title":"J. Young Pharm."},{"key":"18294_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/UA.UA_68_17","volume":"10","author":"A Alamri","year":"2018","unstructured":"Alamri, A. et al. Trend analysis of bacterial uropathogens and their susceptibility pattern: A 4-year (2013\u20132016) study from Aseer region Saudi Arabia. Urol. Ann. 10, 41\u201346. https:\/\/doi.org\/10.4103\/UA.UA_68_17 (2018).","journal-title":"Urol. Ann."},{"key":"18294_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/UA.UA_109_20","volume":"13","author":"A Alamri","year":"2021","unstructured":"Alamri, A., Hassan, B. & Hamid, M. E. Susceptibility of hospital-acquired uropathogens to first-line antimicrobial agents at a tertiary health-care hospital Saudi Arabia. Urol. Ann. 13, 166\u2013170. https:\/\/doi.org\/10.4103\/UA.UA_109_20 (2021).","journal-title":"Urol. Ann."},{"key":"18294_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5530\/jyp.2017.9.69","volume":"9","author":"SS Alavudeen","year":"2017","unstructured":"Alavudeen, S. S. et al. Distribution of multi-resistant bacterial isolates from clinical specimens in a hospital environment of Kingdom of Saudi Arabia. J. Young Pharm. 9, 347\u2013351. https:\/\/doi.org\/10.5530\/jyp.2017.9.69 (2017).","journal-title":"J. Young Pharm."},{"key":"18294_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/mdr.2016.0033","volume":"23","author":"E Albornoz","year":"2017","unstructured":"Albornoz, E. et al. Prevalence of plasmid-mediated quinolone resistance genes in clinical enterobacteria from Argentina. Microb. Drug Resist. 23, 177\u2013187. https:\/\/doi.org\/10.1089\/mdr.2016.0033 (2017).","journal-title":"Microb. Drug Resist."},{"key":"18294_CR26","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.2147\/IDR.S312920","volume":"14","author":"T da Cunha Ferreira","year":"2021","unstructured":"da Cunha Ferreira, T. & Martins, I. S. Risk factors of death in bloodstream infections caused by AmpC beta-lactamase-producing enterobacterales in patients with neoplasia. Infect. Drug Resist. 14, 3083\u20133097. https:\/\/doi.org\/10.2147\/IDR.S312920 (2021).","journal-title":"Infect. Drug Resist."},{"key":"18294_CR27","first-page":"155","volume":"66","author":"W Flores-Paredes","year":"2021","unstructured":"Flores-Paredes, W. et al. Prevalence and antimicrobial resistance of non-ESKAPE-Ec Enterobacteriales in a IV-level hospital in Lima Peru. Acta Microbiologica. Hellenica 66, 155\u2013165 (2021).","journal-title":"Acta Microbiologica. Hellenica"},{"key":"18294_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0732-8893(00)00198-X","volume":"38","author":"PC Fuchs","year":"2000","unstructured":"Fuchs, P. C., Barry, A. L. & Brown, S. D. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria. Diagn. Microbiol. Infect. Dis. 38, 243\u2013253. https:\/\/doi.org\/10.1016\/S0732-8893(00)00198-X (2000).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR29","doi-asserted-by":"publisher","first-page":"609584","DOI":"10.3389\/fmed.2021.609584","volume":"8","author":"H Guan","year":"2021","unstructured":"Guan, H. et al. Distribution and antibiotic resistance patterns of pathogenic bacteria in patients with chronic cutaneous wounds in China. Front. Med. 8, 609584. https:\/\/doi.org\/10.3389\/fmed.2021.609584 (2021).","journal-title":"Front. Med."},{"key":"18294_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2017.09.004","volume":"12","author":"S Guermazi-Toumi","year":"2018","unstructured":"Guermazi-Toumi, S. et al. Susceptibility profiles of bacteria causing urinary tract infections in Southern Tunisia. J. Glob. Antimicrob. Resist. 12, 48\u201352. https:\/\/doi.org\/10.1016\/j.jgar.2017.09.004 (2018).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"18294_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","volume":"33","author":"S Hawser","year":"2023","unstructured":"Hawser, S. et al. In vitro activity of eravacycline and comparators against Gram-negative and gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J. Glob. Antimicrob. Resist. 33, 304\u2013320. https:\/\/doi.org\/10.1016\/j.jgar.2023.04.017 (2023).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"18294_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2009.06.009","volume":"66","author":"DJ Hoban","year":"2010","unstructured":"Hoban, D. J., Bouchillon, S. K., Hawser, S. P. & Badal, R. E. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: Data from the study for monitoring antimicrobial resistance trends 2002 to 2007. Diagn. Microbiol. Infect. Dis. 66, 78\u201386. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.06.009 (2010).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2012.05.024","volume":"74","author":"DJ Hoban","year":"2012","unstructured":"Hoban, D. J. et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: Results from the SMART study 2009\u20132010. Diagn. Microbiol. Infect. Dis. 74, 62\u201367. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.05.024 (2012).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jac\/dkr524","volume":"67","author":"M Hombach","year":"2012","unstructured":"Hombach, M., Bloemberg, G. V. & B\u00f6ttger, E. C. Effects of clinical breakpoint changes in CLSI guidelines 2010\/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J. Antimicrob. Chemother. 67, 622\u2013632. https:\/\/doi.org\/10.1093\/jac\/dkr524 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"18294_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12894-021-00821-8","volume":"21","author":"J Hrbacek","year":"2021","unstructured":"Hrbacek, J., Cermak, P. & Zachoval, R. Current antibiotic resistance patterns of rare uropathogens: Survey from Central European urology department 2011\u20132019. BMC Urol. 21, 61. https:\/\/doi.org\/10.1186\/s12894-021-00821-8 (2021).","journal-title":"BMC Urol."},{"key":"18294_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0924-8579(12)00244-0","volume":"40","author":"PR Hsueh","year":"2012","unstructured":"Hsueh, P. R. Study for monitoring antimicrobial resistance trends (SMART) in the Asia-Pacific region, 2002\u20132010. Int. J. Antimicrob. Agents 40, S1\u2013S3. https:\/\/doi.org\/10.1016\/S0924-8579(12)00244-0 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/antibiotics10070791","volume":"10","author":"N Jain","year":"2021","unstructured":"Jain, N. et al. Antimicrobial resistance in nosocomial isolates of gram-negative bacteria: Public health implications in the Latvian context. Antibiotics 10, 791. https:\/\/doi.org\/10.3390\/antibiotics10070791 (2021).","journal-title":"Antibiotics"},{"key":"18294_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","volume":"47","author":"SS Jean","year":"2016","unstructured":"Jean, S. S. et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the study for monitoring antimicrobial resistance trends (SMART), 2010\u20132013. Int. J. Antimicrob. Agents 47, 328\u2013334. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.01.008 (2016).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10096-008-0610-7","volume":"28","author":"SS Jean","year":"2009","unstructured":"Jean, S. S. et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 28, 215\u2013220. https:\/\/doi.org\/10.1007\/s10096-008-0610-7 (2009).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"18294_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12866-022-02644-5","volume":"22","author":"P Jia","year":"2022","unstructured":"Jia, P. et al. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: The 2018 results from the ATLAS program. BMC Microbiol. 22, 234. https:\/\/doi.org\/10.1186\/s12866-022-02644-5 (2022).","journal-title":"BMC Microbiol."},{"key":"18294_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.eimce.2019.07.003","volume":"38","author":"G Jim\u00e9nez-Guerra","year":"2020","unstructured":"Jim\u00e9nez-Guerra, G. et al. Susceptibility evolution to antibiotics of Enterobacter cloacae, Morganella morganii, Klebsiella aerogenes and Citrobacter freundii involved in urinary tract infections: An 11-year epidemiological surveillance study. Enferm. Infecc. Microbiol. Clin. 38, 166\u2013169. https:\/\/doi.org\/10.1016\/j.eimce.2019.07.003 (2020).","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"18294_CR42","doi-asserted-by":"publisher","first-page":"0265021","DOI":"10.1128\/spectrum.02650-21","volume":"10","author":"Y Jing","year":"2022","unstructured":"Jing, Y. et al. A genomic and bioinformatics view of the classification and evolution of Morganella species and their chromosomal accessory genetic elements harboring antimicrobial resistance genes. Microbiol. Spectr. 10, 0265021 (2022).","journal-title":"Microbiol. Spectr."},{"key":"18294_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1476-0711-3-14","volume":"3","author":"ME Jones","year":"2004","unstructured":"Jones, M. E. et al. Emerging resistance among bacterial pathogens in the intensive care unit\u2013a European and North American surveillance study (2000\u20132002). Ann. Clin. Microbiol. Antimicrob. 3, 14. https:\/\/doi.org\/10.1186\/1476-0711-3-14 (2004).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"18294_CR44","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1128\/AAC.01485-13","volume":"57","author":"JA Karlowsky","year":"2013","unstructured":"Karlowsky, J. A. et al. In vitro activity of ceftaroline-avibactam against Gram-negative and Gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: Results from the CANWARD surveillance study. Antimicrob. Agents Chemother. 57, 5600\u20135611. https:\/\/doi.org\/10.1128\/AAC.01485-13 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18294_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jgar.2022.04.011","volume":"30","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky, J. A. et al. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS global surveillance program from 2018 to 2020. J. Glob. Antimicrob. Resist. 30, 23\u201330. https:\/\/doi.org\/10.1016\/j.jgar.2022.04.011 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"18294_CR46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0924-8579(02)00010-9","volume":"19","author":"JA Karlowsky","year":"2002","unstructured":"Karlowsky, J. A., Jones, M. E., Mayfield, D. C., Thornsberry, C. & Sahm, D. F. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: Results from the surveillance network\u00ae (TSN\u00ae) database-USA. Int. J. Antimicrob. Agents 19, 413\u2013426. https:\/\/doi.org\/10.1016\/s0924-8579(02)00010-9 (2002).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR47","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1128\/AAC.00066-11","volume":"55","author":"JA Karlowsky","year":"2011","unstructured":"Karlowsky, J. A. et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob. Agents Chemother. 55, 3169\u20133175. https:\/\/doi.org\/10.1128\/AAC.00066-11 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18294_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.diagmicrobio.2008.03.005","volume":"61","author":"KS Ko","year":"2008","unstructured":"Ko, K. S. et al. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals. Diagn. Microbiol. Infect. Dis. 61, 453\u2013459. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2008.03.005 (2008).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2147\/IDR.S194482","volume":"12","author":"CC Lai","year":"2019","unstructured":"Lai, C. C. et al. Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: Results from surveillance of multicenter antimicrobial resistance in taiwan (SMART). Infect. Drug Resist. 12, 627\u2013640. https:\/\/doi.org\/10.2147\/IDR.S194482 (2019).","journal-title":"Infect. Drug Resist."},{"key":"18294_CR50","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1469-0691.2006.01474.x","volume":"12","author":"D Lepelletier","year":"2006","unstructured":"Lepelletier, D. et al. Risk-factors for gastrointestinal colonisation with resistant Enterobacteriaceae among hospitalised patients: A prospective study. Clin. Microbiol. Infect. 12, 974\u2013979. https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01474.x (2006).","journal-title":"Clin. Microbiol. Infect."},{"key":"18294_CR51","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s40121-023-00827-9","volume":"12","author":"JX Liao","year":"2023","unstructured":"Liao, J. X. et al. Decreasing antibiotic resistance trends nationally in Gram-negative bacteria across United States Veterans affairs medical centers, 2011\u20132020. Infect. Dis. Ther. 12, 1835\u20131848. https:\/\/doi.org\/10.1007\/s40121-023-00827-9 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"18294_CR52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10096-014-2222-8","volume":"34","author":"TY Lin","year":"2015","unstructured":"Lin, T. Y. et al. Clinical manifestations and prognostic factors of Morganella morganii bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 34, 231\u2013236. https:\/\/doi.org\/10.1007\/s10096-014-2222-8 (2015).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"18294_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0924-8579(03)00108-0","volume":"22","author":"DM Livermore","year":"2003","unstructured":"Livermore, D. M. et al. In vitro activity of piperacillin\/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int. J. Antimicrob. Agents 22, 14\u201327. https:\/\/doi.org\/10.1016\/s0924-8579(03)00108-0 (2003).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1155\/1999\/172031","volume":"10","author":"Low, D.E., de Azavedo, J., Canadian Bacterial Surveillance Network & Davidson, R.","year":"1999","unstructured":"Low, D.E., de Azavedo, J., Canadian Bacterial Surveillance Network & Davidson, R. In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study. Can. J. Infect. Dis. 10, 122\u2013127. https:\/\/doi.org\/10.1155\/1999\/172031 (1999).","journal-title":"Can. J. Infect. Dis."},{"key":"18294_CR55","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0924-8579(12)70008-0","volume":"40","author":"PL Lu","year":"2012","unstructured":"Lu, P. L. et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009\u20132010 results from the study for monitoring antimicrobial resistance trends (SMART). Int. J. Antimicrob. Agents 40, S37\u2013S43. https:\/\/doi.org\/10.1016\/S0924-8579(12)70008-0 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0732-8893(93)90009-v","volume":"16","author":"B Mirelis","year":"1993","unstructured":"Mirelis, B. et al. Increased resistance to quinolone in Catalonia Spain. Diagn. Microbiol. Infect. Dis. 16, 137\u2013139. https:\/\/doi.org\/10.1016\/0732-8893(93)90009-v (1993).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0732-8893(93)90040-e","volume":"17","author":"PR Murray","year":"1993","unstructured":"Murray, P. R., Jones, R. N., Washington, J. A., Gerlach, E. H. & Allen, S. D. In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers. Diagn. Microbiol. Infect. Dis. 17, 307\u2013311. https:\/\/doi.org\/10.1016\/0732-8893(93)90040-e (1993).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR58","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.wem.2020.01.002","volume":"31","author":"ND Ngo","year":"2020","unstructured":"Ngo, N. D. et al. Clinical features, bacteriology, and antibiotic treatment among patients with presumed Naja bites in Vietnam. Wilderness Environ. Med. 31, 151\u2013156. https:\/\/doi.org\/10.1016\/j.wem.2020.01.002 (2020).","journal-title":"Wilderness Environ. Med."},{"key":"18294_CR59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/jac\/dkn068","volume":"61","author":"JD Pitout","year":"2008","unstructured":"Pitout, J. D., Wei, Y., Church, D. L. & Gregson, D. B. Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary health region, Canada: The emergence of aac(6\u2032)-Ib-cr. J. Antimicrob. Chemother. 61, 999\u20131002. https:\/\/doi.org\/10.1093\/jac\/dkn068 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"18294_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0732-8893(94)00087-d","volume":"21","author":"BL Prosser","year":"1995","unstructured":"Prosser, B. L. & Beskid, G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diagn. Microbiol. Infect. Dis. 21, 33\u201345. https:\/\/doi.org\/10.1016\/0732-8893(94)00087-d (1995).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.3.345","author":"DS Reeves","year":"1993","unstructured":"Reeves, D. S., Bywater, M. J. & Holt, H. A. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres. J. Antimicrob. Chemother. https:\/\/doi.org\/10.1093\/jac\/31.3.345 (1993).","journal-title":"J. Antimicrob. Chemother."},{"key":"18294_CR62","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0732-8893(02)00433-9","volume":"44","author":"KV Rolston","year":"2002","unstructured":"Rolston, K. V., Frisbee-Hume, S., LeBlanc, B. M., Streeter, H. & Ho, D. H. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn. Microbiol. Infect. Dis. 44, 187\u2013194. https:\/\/doi.org\/10.1016\/s0732-8893(02)00433-9 (2002).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"18294_CR63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s15010-022-01762-6","volume":"50","author":"F Schaumburg","year":"2022","unstructured":"Schaumburg, F. et al. Chronic wounds in Sierra Leone: Pathogen spectrum and antimicrobial susceptibility. Infection 50, 907\u2013914. https:\/\/doi.org\/10.1007\/s15010-022-01762-6 (2022).","journal-title":"Infection"},{"key":"18294_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/s0924-8579(99)00091-6","volume":"12","author":"FJ Schmitz","year":"1999","unstructured":"Schmitz, F. J., Verhoef, J. & Fluit, A. C. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. Int. J. Antimicrob. Agents 12, 311\u2013317. https:\/\/doi.org\/10.1016\/s0924-8579(99)00091-6 (1999).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"18294_CR65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000316373","volume":"19","author":"S Senel","year":"2010","unstructured":"Senel, S., Karacan, C., Erkek, N. & Gol, N. A single-center experience of antimicrobial resistance patterns in pediatric urinary tract infection. Med. Princ. Pract. 19, 359\u2013363. https:\/\/doi.org\/10.1159\/000316373 (2010).","journal-title":"Med. Princ. Pract."},{"key":"18294_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jac\/43.suppl_3.51","volume":"43","author":"HH Siegrist","year":"1999","unstructured":"Siegrist, H. H., Nepa, M. C. & Jacquet, A. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology oncology patients in Switzerland: A multicentre study. J. Antimicrob. Chemother. 43, 51\u201354. https:\/\/doi.org\/10.1093\/jac\/43.suppl_3.51 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"18294_CR67","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1128\/AAC.47.10.3089-3098.2003","volume":"47","author":"RP Wenzel","year":"2003","unstructured":"Wenzel, R. P. et al. In vitro susceptibilities of Gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000\u20132001 to expanded-spectrum cephalosporins and comparator antimicrobials: Implications for therapy. Antimicrob. Agents Chemother. 47, 3089\u20133098. https:\/\/doi.org\/10.1128\/AAC.47.10.3089-3098.2003 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18294_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1069-417X(95)80001-8","volume":"4","author":"YC Yee","year":"1995","unstructured":"Yee, Y. C. & Thornsberry, C. A survey of ciprofloxacin and 11 other antimicrobial agent susceptibility data of United States bacterial isolates from 1990 to 1992. Antimicrob. Infect. Dis. Newsl. 4, 1\u201318. https:\/\/doi.org\/10.1016\/1069-417X(95)80001-8 (1995).","journal-title":"Antimicrob. Infect. Dis. Newsl."},{"key":"18294_CR69","doi-asserted-by":"publisher","first-page":"52","DOI":"10.11604\/pamj.2022.42.52.31042","volume":"42","author":"MD Yefou","year":"2022","unstructured":"Yefou, M. D. et al. Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon. Pan. Afr. Med. J. 42, 52. https:\/\/doi.org\/10.11604\/pamj.2022.42.52.31042 (2022).","journal-title":"Pan. Afr. Med. J."},{"key":"18294_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijid.2016.07.006","volume":"50","author":"H Liu","year":"2016","unstructured":"Liu, H., Zhu, J., Hu, Q. & Rao, X. Morganella morganii, a non-negligent opportunistic pathogen. Int. J. Infect. Dis. 50, 10\u201317. https:\/\/doi.org\/10.1016\/j.ijid.2016.07.006 (2016).","journal-title":"Int. J. Infect. Dis."},{"key":"18294_CR71","doi-asserted-by":"publisher","first-page":"1464736","DOI":"10.3389\/fcimb.2024.1464736","volume":"14","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. Genomic epidemiology and antimicrobial resistance of Morganella clinical isolates between 2016 and 2023. Front. Cell Infect. Microbiol. 14, 1464736. https:\/\/doi.org\/10.3389\/fcimb.2024.1464736 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"18294_CR72","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3747\/pdi.2016.00268","volume":"37","author":"V Keskar","year":"2017","unstructured":"Keskar, V., Biyani, M., Amin, S. O. & Knoll, G. Successful treatment of PD peritonitis due to Morganella morganii resistant to third-generation cephalosporins \u2014 A case report. Perit. Dial. Int. 37, 241\u2013242. https:\/\/doi.org\/10.3747\/pdi.2016.00268 (2017).","journal-title":"Perit. Dial. Int."},{"key":"18294_CR73","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1179\/joc.2005.17.5.484","volume":"17","author":"GT Hansen","year":"2005","unstructured":"Hansen, G. T. & Blondeau, J. M. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 17, 484\u2013492. https:\/\/doi.org\/10.1179\/joc.2005.17.5.484 (2005).","journal-title":"J. Chemother."},{"key":"18294_CR74","first-page":"5","volume":"16","author":"F Luzzaro","year":"2008","unstructured":"Luzzaro, F. Fluoroquinolones and Gram-negative bacteria: Antimicrobial activity and mechanisms of resistance. Infez. Med. 16, 5\u201311 (2008).","journal-title":"Infez. Med."},{"key":"18294_CR75","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jgar.2019.07.031","volume":"20","author":"TTH Van","year":"2020","unstructured":"Van, T. T. H., Yidana, Z., Smooker, P. M. & Coloe, P. J. Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses. J. Glob. Antimicrob. Resist. 20, 170\u2013177. https:\/\/doi.org\/10.1016\/j.jgar.2019.07.031 (2020).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"18294_CR76","doi-asserted-by":"publisher","first-page":"2411919121","DOI":"10.1073\/pnas.2411919121","volume":"121","author":"EY Klein","year":"2024","unstructured":"Klein, E. Y. et al. Global trends in antibiotic consumption during 2016\u20132023 and future projections through 2030. Proc. Natl. Acad. Sci. U. S. A. 121, 2411919121. https:\/\/doi.org\/10.1073\/pnas.2411919121 (2024).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"18294_CR77","doi-asserted-by":"publisher","first-page":"174286","DOI":"10.1016\/j.scitotenv.2024.174286","volume":"946","author":"S Kuppusamy","year":"2024","unstructured":"Kuppusamy, S., Venkateswarlu, K. & Megharaj, M. Tetracycline and fluoroquinolone antibiotics contamination in agricultural soils fertilized long-term with chicken litter: Trends and ravages. Sci. Total Environ. 946, 174286. https:\/\/doi.org\/10.1016\/j.scitotenv.2024.174286 (2024).","journal-title":"Sci. Total Environ."},{"key":"18294_CR78","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/jac\/dkx492","volume":"73","author":"CF Lee","year":"2018","unstructured":"Lee, C. F. et al. Impact of antibiotic stewardship programmes in Asia: A systematic review and meta-analysis. J. Antimicrob. Chemother. 73, 844\u2013851. https:\/\/doi.org\/10.1093\/jac\/dkx492 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"18294_CR79","doi-asserted-by":"publisher","first-page":"1153048","DOI":"10.3389\/fvets.2023.1153048","volume":"10","author":"R Gehring","year":"2023","unstructured":"Gehring, R., Mochel, J. P. & Schmerold, I. Understanding the background and clinical significance of the WHO, WOAH, and EMA classifications of antimicrobials to mitigate antimicrobial resistance. Front. Vet. Sci. 10, 1153048. https:\/\/doi.org\/10.3389\/fvets.2023.1153048 (2023).","journal-title":"Front. Vet. Sci."},{"key":"18294_CR80","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.infpip.2019.100019","volume":"1","author":"J Chin","year":"2019","unstructured":"Chin, J. et al. Restriction-free antimicrobial stewardship initiative targeting fluoroquinolone reduction across a regional health-system. Infect. Prev. Pract. 1, 100019. https:\/\/doi.org\/10.1016\/j.infpip.2019.100019 (2019).","journal-title":"Infect. Prev. Pract."},{"key":"18294_CR81","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12879-023-08398-3","volume":"23","author":"CJ Pallares","year":"2023","unstructured":"Pallares, C. J. et al. Antimicrobial stewardship programs in seven Latin American countries: Facing the challenges. BMC Infect. Dis. 23, 463. https:\/\/doi.org\/10.1186\/s12879-023-08398-3 (2023).","journal-title":"BMC Infect. Dis."},{"key":"18294_CR82","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clinmicnews.2021.06.001","volume":"43","author":"AS Maris","year":"2021","unstructured":"Maris, A. S., Mody, P., Brewer, D. J. & Humphries, R. M. The fluoroquinolones: An update for the clinical microbiologist. Clin. Microbiol. Newsl. 43, 97\u2013107. https:\/\/doi.org\/10.1016\/j.clinmicnews.2021.06.001 (2021).","journal-title":"Clin. Microbiol. Newsl."},{"key":"18294_CR83","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","volume":"22","author":"LS Redgrave","year":"2014","unstructured":"Redgrave, L. S., Sutton, S. B., Webber, M. A. & Piddock, L. J. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 22, 438\u2013445. https:\/\/doi.org\/10.1016\/j.tim.2014.04.007 (2014).","journal-title":"Trends Microbiol."},{"key":"18294_CR84","doi-asserted-by":"publisher","first-page":"025320","DOI":"10.1101\/cshperspect.a025320","volume":"6","author":"DC Hooper","year":"2016","unstructured":"Hooper, D. C. & Jacoby, G. A. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 6, 025320. https:\/\/doi.org\/10.1101\/cshperspect.a025320 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"18294_CR85","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya, O. et al. Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 61, e01443-e1517. https:\/\/doi.org\/10.1128\/AAC.01443-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18294_CR86","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1017\/ash.2022.326","volume":"2","author":"EA Swingler","year":"2022","unstructured":"Swingler, E. A. et al. Fluoroquinolone stewardship at a community health system: A decade in review. Antimicrob. Steward. Healthc. Epidemiol. 2, 186. https:\/\/doi.org\/10.1017\/ash.2022.326 (2022).","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"18294_CR87","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cmi.2018.05.021","volume":"25","author":"J \u00c5hman","year":"2019","unstructured":"\u00c5hman, J., Matuschek, E. & Kahlmeter, G. The quality of antimicrobial discs from nine manufacturers-EUCAST evaluations in 2014 and 2017. Clin. Microbiol. Infect. 25, 346\u2013352. https:\/\/doi.org\/10.1016\/j.cmi.2018.05.021 (2019).","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18294-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18294-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:46:20Z","timestamp":1759751180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18294-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18294"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18294-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34746"}}